Zerlasiran sodium

• CAT Number: I040324
• Molecular Formula: C443H556F12N144Na38O277P40S10
• Molecular Weight: 14991.12
• Purity: ≥95%

Zerlasiran sodium(CAT: I040324) is an investigational antisense oligonucleotide designed to selectively reduce the synthesis of apolipoprotein(a) [Apo(a)], a key component of lipoprotein(a) [Lp(a)], which is associated with elevated cardiovascular risk. By targeting Apo(a) mRNA, Zerlasiran suppresses hepatic production of Lp(a), offering a promising therapeutic approach for managing atherosclerotic cardiovascular disease in patients with genetically elevated Lp(a) levels. Developed for high specificity and long-lasting action, Zerlasiran sodium represents a next-generation agent in lipid-lowering and cardiovascular risk-reduction research. It is a valuable tool in preclinical and clinical studies exploring novel treatments for hyperlipoproteinemia.